Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827892 · ClinicalTrials.gov registry record · Phase 2
Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00827892 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 84 participants.
The verdict
NCT00827892, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes. In an effort to develop a new treatment for ICH, this research focuses on a different aspect of ICH treatment which has not yet been evaluated: enhancing absorption of the blood clot with medication.
Interventions
- DRUG Pioglitazone
- DRUG Placebo Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827892
The ClinicalTrials.gov registry entry for NCT00827892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00827892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827892 about?
NCT00827892 is a clinical study titled "Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage". Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes. In an effort to develop a new treatment for ICH, this research focuses on a different aspe...
What is the current status of trial NCT00827892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2009-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00827892?
The interventions under investigation include: Pioglitazone (DRUG), Placebo Control (DRUG).
Who is sponsoring clinical trial NCT00827892?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.